Daniel OBrien
Overview
Explore the profile of Daniel OBrien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
1307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Starlinger P, Brunnthaler L, McCabe C, Pereyra D, Santol J, Steadman J, et al.
JHEP Rep
. 2023 Mar;
5(4):100683.
PMID: 36950091
Background & Aims: Although extensive experimental evidence on the process of liver regeneration exists, in humans, validation is largely missing. However, liver regeneration is critically affected by underlying liver disease....
12.
Kim J, Waugh D, Zaitchik B, Luong A, Bergmark R, Lam K, et al.
Int Forum Allergy Rhinol
. 2022 Dec;
13(5):865-876.
PMID: 36575965
Background: The escalating negative impact of climate change on our environment has the potential to result in significant morbidity of rhinologic diseases. Methods: Evidence based review of examples of rhinologic...
13.
Darlow B, Krageloh C, Abbott J, Bennell K, Briggs A, Brown M, et al.
Musculoskeletal Care
. 2022 Dec;
21(2):516-526.
PMID: 36573463
Objective: Accurate knowledge is central to effective self-care of osteoarthritis (OA). This study aimed to assess the measurement properties of the Osteoarthritis Knowledge Scale (OAKS) with versions for the hip...
14.
Darlow B, Abbott H, Bennell K, Briggs A, Brown M, Clark J, et al.
Osteoarthr Cartil Open
. 2022 Dec;
3(2):100160.
PMID: 36474995
Objectives: 1) Develop unidimensional instruments to measure osteoarthritis (OA) knowledge among people with hip or knee OA, and 2) assess the structural validity, internal consistency, cross-cultural validity/measurement invariance, test-retest reliability,...
15.
Carr M, Friedel J, OBrien D, Foreman A, Wirth O
Cureus
. 2022 Oct;
14(9):e28929.
PMID: 36237775
Introduction: The Accreditation Council for Graduate Medical Education (ACGME), which sets the standards for residency training, instituted work-hour restrictions in 2003. Our purpose was to assess residents' perceptions of fatigue...
16.
Tay A, Jiang Y, Signal N, OBrien D, Chen J, Murphy R, et al.
Front Nutr
. 2022 Oct;
9:1000510.
PMID: 36211508
Introduction: Pharmaceutical drugs are beneficial to inflammatory conditions but with side effects, which led to the search for alternative therapies. , the New Zealand green-lipped mussel, have shown promise in...
17.
Conboy C, Yonkus J, Buckarma E, Mun D, Werneburg N, Watkins R, et al.
J Hepatol
. 2022 Sep;
78(1):142-152.
PMID: 36162702
Background & Aims: There is an unmet need to develop novel, effective medical therapies for cholangiocarcinoma (CCA). The Hippo pathway effector, Yes-associated protein (YAP), is oncogenic in CCA, but has...
18.
Borad M, Bai L, Richards D, Mody K, Hubbard J, Rha S, et al.
Hepatology
. 2022 Sep;
77(3):760-773.
PMID: 36152015
Background And Aims: This study aimed to investigate safety and efficacy of silmitasertib, an oral small molecule casein kinase 2 inhibitor, plus gemcitabine and cisplatin (G+C) versus G+C in locally...
19.
Zhang X, OBrien D, Zhang X
Oxid Med Cell Longev
. 2022 Sep;
2022:7078787.
PMID: 36071863
Background: Basal-like breast cancer (BLBC) exhibits worse pathological features than other breast cancer subtypes, and patients diagnosed with BLBC have short disease-free and overall survival times. Thus, the identification of...
20.
Nicolas C, VanLith C, Hickey R, Du Z, Hillin L, Guthman R, et al.
Nat Commun
. 2022 Aug;
13(1):5012.
PMID: 36008405
Conventional therapy for hereditary tyrosinemia type-1 (HT1) with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) delays and in some cases fails to prevent disease progression to liver fibrosis, liver failure, and activation of tumorigenic pathways....